Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial

ABOUT THIS EPISODE

Originally aired: February 2, 2026 

CHEST February 2026, Volume 169, Issue 2

James Cheng Chung Wei, MD, PhD, and Po-Cheng Shih, MD, join CHEST^® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss their research into the comparative effectiveness and safety of tocilizumab and rituximab in patients with rheumatoid arthritis-associated interstitial lung disease.

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

Moderator
Alice Gallo De Moraes, MD, FCCP

Also available